I'm the founder and CEO of Science Exchange, a marketplace for scientific collaboration where researchers can order experiments from the world's best labs.

The decision to initiate the reproducibility initiative was a game-changer for Science Exchange, enhancing its branding and opening doors to pharmaceutical partnerships.

Despite facing a down round during our Series C funding, we continued to grow the business and raise additional capital, demonstrating resilience in a competitive market.

In a hundred years, Science Exchange will continue to enable scientific breakthroughs by providing infrastructure for collaboration among researchers.

I'm Elizabeth Iorns, the founder and CEO of Science Exchange, and I have a background in cancer biology, having completed my PhD at the Institute of Cancer Research in London and a postdoc at the University of Miami before starting Science Exchange in 2011 as part of Y Combinator's summer batch.

I started Science Exchange because I saw how scientific research was evolving and becoming more specialized and multidisciplinary, which made collaborations inefficient.

We raised our Series A after initially facing many rejections, but ultimately secured $3-4 million from various investors.

I'm Elizabeth Iorns, founder and CEO of Science Exchange, a marketplace for outsourced research and development, working with major pharmaceutical and science companies.

I started Science Exchange to solve my own problem as a breast cancer researcher who was frustrated with the process of farming out experiments.